COVID vaccine immunity is waning - how much does that matter?

@article{Dolgin2021COVIDVI,
  title={COVID vaccine immunity is waning - how much does that matter?},
  author={Elie S. Dolgin},
  journal={Nature},
  year={2021}
}
  • E. Dolgin
  • Published 17 September 2021
  • Philosophy
  • Nature
Machine learning models for Prediction of the need for future Covid-19 vaccine booster
About 4 million Virginia citizens are fully vaccinated against COVID-19. According to medical data from nations like Israel and the United Kingdom, all those people may require another shot in the
Immunogenicity and Safety of Homologous and Heterologous Prime–Boost Immunization with COVID-19 Vaccine: Systematic Review and Meta-Analysis
TLDR
It is suggested that now, only individuals primed with inactivated vaccines require a booster dose, and the administration of the booster dose effectively recalled specific immune responses to SARS-CoV-2 and increased antibody levels, especially in heterologous immunization.
Effectiveness of Arsenicum album 30C in Prevention of COVID-19 in Individuals Residing in Containment Zones of Delhi-A Prospective, Community-based, Parallel Cohort Study.
OBJECTIVE  This work was designed as undertaken to evaluate the protective effect of Arsenicum album 30C against COVID-19. DESIGN  The work was designed as a prospective parallel cluster cohort
A Comparison Between Omicron and Earlier COVID-19 Variants' Disease Severity in the Milan Area, Italy
In the context of the fourth wave of the COVID-19 pandemic in Italy, which occurred in correspondence with the outbreak of the Omicron variant, it became fundamental to assess differences in the risk
Machine Learning models for Customer Relationship Analysis to Improve Satisfaction Rate in Banking
The purpose of this research project was to analyze customer complaint data from financial institutions and identify areas of opportunity for these institutions to improve their customer satisfaction
Persistence of immune responses to the Sinopharm/BBIBP‐CorV vaccine
TLDR
To determine the kinetics and persistence of immune responses following the Sinopharm/BBIBP‐CorV, immune responses in a cohort of Sri Lankan individuals are investigated.
Percentages of Vaccination Coverage Required to Establish Herd Immunity against SARS-CoV-2
TLDR
It is found that high percentages of vaccination coverage and high levels of vaccination effectiveness are necessary to block the transmission of Omicron and other SARS-CoV-2 variants with greater infectious capacity.
Timing the race of vaccination, new variants, and relaxing restrictions during COVID-19 pandemic
Risk Factors and Incidence Rates of Covid-19 Breakthrough Infections in Vaccinated People in General Medicine Practice in Toledo (Spain)
TLDR
COVID-19 breakthrough infections in vaccinated people were rare, with higher rates in women and old people, and the Janssen vaccine posed a strong risk; however, the small numbers prevent definitive conclusions.
...
...

References

SHOWING 1-10 OF 14 REFERENCES
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
TLDR
Through 6 months of follow-up and despite a gradual decline in vaccine efficacy, BNT162b2 had a favorable safety profile and was highly efficacious in preventing Covid-19.
Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
TLDR
It is found that the rates of confirmed Covid-19 and severe illness were substantially lower among those who received a booster (third) dose of the BNT162b2 vaccine.
Durability analysis of the highly effective BNT162b2 vaccine against COVID-19
TLDR
The odds of experiencing a non-COVID-19 hospitalization decreased with time since vaccination, suggesting a possible underestimation of waning protection by this approach due to confounding factors and providing reassurance that BNT162b2 continues to protect against symptomatic SARS-CoV-2 infection several months after full vaccination.
Waning immunity of the BNT162b2 vaccine: A nationwide study from Israel
TLDR
Quantifying the effect of waning immunity on vaccine effectiveness is critical for policy makers worldwide facing the dilemma of administering booster vaccinations after six months after a mass vaccination campaign against coronavirus.
Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar
TLDR
BNT162b2-induced protection against infection appears to wane rapidly after its peak right after the second dose, but it persists at a robust level against hospitalization and death for at least six months following the seconddose.
mRNA Vaccination Induces Durable Immune Memory to SARS-CoV-2 with Continued Evolution to Variants of Concern
TLDR
It is observed that boosting of pre-existing immunity with mRNA vaccination in SARS-CoV-2 recovered individuals primarily increased antibody responses in the short-term without significantly altering antibody decay rates or long-term B and T cell memory.
Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants
TLDR
Binding and functional antibodies against variants persisted in most subjects, albeit at low levels, for 6-months after the primary series of the mRNA-1273 vaccine, which complement ongoing studies to inform the potential need for additional boost vaccinations.
Rates of SARS-CoV-2 transmission and vaccination impact the fate of vaccine-resistant strains
TLDR
It is shown that a period of transmission reduction close to the end of the vaccination campaign can substantially reduce the probability of resistant strain establishment and suggest that policymakers and individuals should consider maintaining non-pharmaceutical interventions and transmission-reducing behaviours throughout the entire vaccination period.
...
...